**Table S1: Systematic search strategy**

|  |  |  |
| --- | --- | --- |
| Search | PubMed Search Query 03 October 2019 | Hits |
| #1 | Atopic AND Dermatitis | 27232 |
| #2 | atopic AND eczema | 7162 |
| #3 | autoreactivity OR autoreactive OR autoreactiv\* OR self-reactiv\* | 11389 |
| #4 | anti-IgE OR (anti AND IgE) OR (auto AND IgE) OR (auto AND anti AND IgE) | 12233 |
| #5 | autoantigen\* OR autoallergen | 26699 |
| #6 | autoallergy | 71 |
| #7 | autoimmunity OR autoimmune OR (autoimmune AND disease\*) | 197058 |
| #8 | autoantibodies OR (IgE AND autoantibodies) OR (IgG AND autoantibodies) | 11087 |
| #9 | autoreactive AND T cells | 5941 |
| #10 | #1 OR #2 | 28190 |
| #11 | #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 | 291205 |
| #11 | #10 AND #11 | 1552 |

**Table S2: Systematic search on IgE autoantibodies in patients with atopic dermatitis**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **References** | **Study design** | **Population size (n)** | **Age: mean (****sd/range)** | **AD diagnostic criteria** | **Measurement of autoreactivity** | **Prevalence of auto-IgE in patients with AD** | **Prevalence of auto-IgE in control group** |
| Aichberger et al., 2005 (37) | Case-control | AD, n=12RC without AD, n=11NA, n=6NA with CD, n=3NA with PS, n=3 | 38.5 (20-72) | Hanfin and Rajka | Western BlotSerum IgE against epithelial cell line A 431 and rHom s 4 | A342: 91,7% (11/12)Hom s 4: 16,7% (2/12) | 0% (0/23) |
| Altrichter et al., 2008 (35) | Case-control | AD, n=192HC, n=5 | AD: 39 (18-80)NA: 3 (25-64) | Hanfin and Rajka | Western BlotSerum IgE against epithelial cell line A 431 and/ or epidermis | 28% (54/192) | 0% (0/26) |
| Guarneri et al., 2015 (109) | Case-control | AD, n=27HC, n= 27 | AD: 22.2(12.2)Range: 5-49 | Hanfin and Rajka | Skin prick test against hMnSOD | 14.8% (4/27) | 0% (0/27) |
| Hide et al., 2002 (54) | Case-control | AD, n=66AR without AD, n=7HC, n=27 | AD: 24.7 (5.2)AR without AD: 24.6 (4.8)HC: 27.8(6.7) | Rajka and Langeland | Skin test against autologous sweat | 84.8% (56/66) | HC: 11.1% (3/27)AR: 71.4% (5/7) |
| Kawamoto et al., 2003 (30) | Case-control | AD, n=40HC, n= 41 | AD: 26.4 (12-44)HC: 29.2 (19-54) |  | ELISACTL-directed peptidesSART3109SART3315CypB84CypB91ART475 | 2.5% (1/40)37.5% (15/40)15% (6/40)27.5% (11/40)17.5% (7/40)10% (4/40) | 4.9% (2/41)29.3% (12/41)17.1% (7/41)29.3% (12/41)31.7% (13/41)12.2% (5/41) |
| Kortekangas-Savolainen et al., 2004 (33) | Case-control | IgE- mediated AEDS: n=27HC: n=6UA: n=4PS: n=3 | AD: 33(11)HC: 47 |  | Western blotSerum IgE against keratinocytes | 37% (10/27) | 0% (0/13) |
| Mitterman et al., 2008 (38) | Case-control  | AD: n=11RC: n=7CA: n= 5NA: n=9 | AD: 31.9(14.9)Controls: 35.2(10.9) | Hanfin and Rajka | ImmunoblottingIgE against epithelial cell-line A431 | 72.7% (8/11) | 0% (0/12) |
| Mothes et al., 2005 (20) | Case-control | AD: n=174PS: n=10HC: n=26 | AD: 35.4 (14.8)HC: 36.5 (16.5) | Hanfin and Rajka | ImmunoblottingIgE against epithelial cell-derived antigens | 23% (40/174) | 0%(0/10) |
| Natter et al., 1998 (19) | Case series | AD, n=51 | AD: 26.9 (18.6)Range: 1-63 | Hanfin and Rajka | Western blotSerum IgE against endothelial cells and A431 | 43.1% (22/51) | / |
| Ochs et al., 2000 (57) | Case series | AD: n=64 | AD: 24.4(4-34) | Hanfin and Rajka | Western blotIgE against DFS70 | 62.5% (10/16) | 0% (0/1) |
| Schmid-Grendelmeier et al., 2005 (34) | Case-control study | AD, n=69HC, n=5PS, n=13ABPA, n=11*A.fumigatus*, n=13 | AD: 29.3(5.6)Other: 25.3 | Hanfin and Rajka | ELISAagainst rhMnSOD | 42% (29/69) | ABPA: 100% (11/11)Other: 0% |
| Tanaka et al., 2006 (55) | Case-control | AD, n=62PS, n=13HC, n=46 | AD: 24.0 (7.5)Range: 2-43PS: 53.4 (17)Range: 29-73HC: 28.4 (9)Range: 1-52 | / | Dot blotting of IgE against purified sweat antigen | 77.0% (47/61) | 8.7% (4/46) |
| Valenta et al., 1996 (17) | Case-control | AD, n=20HC, n=28 | AD: 35.3(12.3)HC: 33(11.4) | Hanifin and Rajka | Western BlotIgE against endothelial cells, platelets, fibroblast and epithelial cells | 60% (12/20) | 0% (0/28) |
| Watanabe et al., 2011 (31) | Case-control  | AD, n=61HC, n=20 | AD: 26.2 (9.8) Range: 13-59HC: 33.1 (9.5) Range: 22-57 | Hanifin and Rajka | ELISA against DFS70 | 14.8% (9/61) | 0% (0/20) |
| Zeller et al., 2009 (36) | Case-control study | AD, n=71PS, n=12HC, n=24 | AD: 33.35(12.7)HC: 29(3.71) | Hanifin and Rajka/EAACI | Immunoblotting and ELISAactin-alpha, eIF6, RPI, HLA-DR-alpha and tubulin-alpha | AD: 71,8% (51/71) | Non-AD: 72,2%(13/18) |

**Table S3: Autoreactive T-cells in patients with atopic dermatitis**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| References | Population size (n) | Age: mean (sd/range) | Diagnostic criteria for AD | Stimulation with (auto)antigen | T cell autoreactivity in patients with AD |
| *Aichberger et al., 2005* (37) | AD, n=12RC no AD, n=11,NA, n=6,CD, n=3,PS, n=3  | AD: 38.4 (20-72) | Hanifin and Rajka | Hom s 4  | Th1-biased immune response through IFN-ɣ |
| *Balaji et al., 2011* (114) | AD s, n=3, AD ns, n=3PS ns, n=3,HC, n=5 | AD: 42 (21-66) | Hanifin and Rajka | Mala s 13/hTrx | Increased proliferation of lymphocytes in PBMCs. Mala s 13-specific TCL and TCC cells show full cross-reactivity with hTrx. Mala S 13-specific TCC are mainly CD4+ and express CLA. TCCs belonging to TH1, TH2, TH17 and TH22 phenotypes |
| *Heratizadeh et al., 2011* (115) | AD, n= 30HC, n= 1 | AD: 36 (12) | Hanifin and Rajka | α-NAC | Proliferation of CCR4+ and CLA+  |
| *Hradetzky et al., 2014* (75) | AD, n=11, AD ns, n=12HC, n=18 | AD: 40 | SCORAD | α-NAC | Increased secretion of IFN-ɣ, IL-17 and IL-22 in α-NAC stimulated PMBCs. Lower levels of IL-10 produced in α-NAC stimulated PMBC’s |
| *Kapitein et al., 2013* (116) | AD, n= 55HC, n=30 | AD: 8.8 (1.5-17.5)HC: 8.6 (1.2-17.3) | Hanifin and Rajka | hsp60 | Increased presence of hsp60 in AD childrenHigher T cell proliferationHigh levels of IFN-ɣ and less IL-10 production by hsp60-reactive T cells (CD4+CD14+)hsp60-induced CD4+CD25+CD127- T cells are not suppressive in vitro |
| *Lind et al., 2009* (117) | AD, n=78HC, n=45 | AD: 29 (18-65)HC: 39 (20-64)\* | UK Working Party’s Diagnostic criteria | *M. sympodialis* | Elevated plasma levels of IL-18Activation of iNKT-cells, release of IFN-ɣ |
| *Roesner et al., 2016* (106) | AD, n=12HC, n=9HLA-A\*02+ AD, n=15HLA-A\*02 PS, n=3HLA-A\*02+ HC, n= 12 |  | Hanifin and Rajka | α-NAC | Strong proliferation of α-NAC specific CD8+ T cells, secreting IL-4 and IFN-ɣ. Higher frequencies of α-NAC specific CD8+ T cells vs HC. Increased numbers of CD8+/CD45RA-/CD127-TEM and CD8+/CD45RA+/CD27- TEMRA CD8+ subsets |
| *Schmid-Grendelmeier et al., 2005* (34) | AD, n= 69PS, n= 13*A. fumigatus*, n=13ABPA, n=11; HC, n=5 | AD: 29.3 (5.6)HC: 22.3 (4.9) | Hanifin and Rajka | hMnSOD*M. sympodialis**A. Fumigatus*Asp f6 | Higher proliferation rate of T cells in hMnSOD sensitized patients |